New immunotherapies and targeted therapies are progressing rapidly through clinical stages and launching innovative platforms. Janux Therapeutics presented promising pipeline data for autoimmune disease candidates. Dispatch Bio launched with $216 million backing and a novel CAR-T associated platform targeting a broad range of solid tumors through a universal antigen, Flare. AstraZeneca's gefurulimab achieved positive Phase 3 results for myasthenia gravis, a rare autoimmune disorder, supporting regulatory filings. Research reveals autoantibodies may significantly boost patient responses to checkpoint immunotherapy, opening new approaches to overcoming treatment resistance in cancer.